Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
INVECTYS INC TO PARTICIPATE IN THE 2021 ROTH VIRTUAL globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Invectys, Inc appoints Biopharma Veteran, Praveen Tyle, PhD as President & CEO
Invectys, Inc.May 4, 2021 GMT
Houston, TX, USA, May 04, 2021 (GLOBE NEWSWIRE) Invectys, Inc., a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products for cancer patients, today announced the appointment of Praveen Tyle, PhD, as President & CEO and election to its Board of Directors. Dr. Tyle brings over 35 years of experience in both large and small pharma and biotech companies, most recently serving as Executive V.P. for Research and Development of the public company, Lexicon Pharmaceuticals, Inc. Earlier, Dr. Tyle served as the Corporate Senior Vice President and Chief Scientific Officer of Bausch and Lomb and then as Senior Vice President and Global Head of Business Development and R&D at Novartis OTC. Subsequently, Dr. Tyle joined